Sign in to fuzzto save your conversations, follow your research and come back anytime.
Concord Biotech
CONCORDBIO
NSE
BSE
NSEBSESectorHealthcare
1,447.70
Loading chart…
About the company
Concord Biotech Limited is an India-based biopharma company that develops and manufactures fermentation-based APIs and formulations. It focuses on immunosuppressants, oncology, anti-infectives, nephrology, and critical care. The company operates three manufacturing facilities in Gujarat, India, with a total annual installed fermentation capacity of 1,250 m3 for APIs. Concord Biotech supplies products to over 70 countries, including regulated markets like the United States, Europe, and Japan. The company was originally incorporated in 1984, acquired by Sudhir Vaid in 2000, and launched its formulation business in 2016. It went public in August 2023 through an Initial Public Offer.
In the news
Concord Biotech Q1 profit jumps 32.84% to ₹58.53 crore
Concord Biotech clears Kenya, Uganda regulatory inspections
Concord Biotech completes ANVISA inspection at Limbasi facility
Trading Ideas: 7 Stocks to Watch on June 11
Concord Biotech shares surge 8% on US FDA approval amid market volatility
Concord Biotech shares surge 8.46% on USFDA approval for Mycophenolate Mofetil
Sensex Falls 117 Points After RBI Policy; Infrastructure Stocks Hit
Concord Biotech Q4 profit drops 37% to ₹88.8 crore; gets FDA nod
Anand Rathi recommends Castrol India, Concord Biotech for May 6